Chinese Composites Market Analysis 2024-2030: Innovative Trends include Ultra-High Modulus Glass Fiber and Increasing Penetration of Aramid Fiber Advances in Head Protection Application
DUBLIN, March 25, 2024 /PRNewswire/ — The “Chinese Composites Market: Market Size, Trends and Growth Analysis” report has been added to ResearchAndMarkets.com’s offering. The future of the Chinese composites market looks promising with opportunities in transportation, marine
Trucept Inc. Achieves Remarkable Financial Milestones in 2023
ESCONDIDO, Calif., March 25, 2024 /PRNewswire/ — Trucept Inc. (OTC Pink: TREP) is pleased to announce significant achievements in its financial performance for the fiscal year 2023. “We are thrilled to announce these outstanding financial achievements for the fiscal year 2023,” sa
Hancom announces strategic investment in Spanish AI biometric company FacePhi
Hancom acquires exclusive business rights to FacePhi in APAC regionHancom to establish bridgehead for entering the overseas AI market by selling under Hancom brand (white labeling) FacePhi holds facial recognition technology with world-class security BARCELONA and SEOUL, South Korea, March 25, 2024
ESChat and JPS deliver a Next Generation LMR to Broadband Push-to-Talk Interoperability Solution
The next generation solution provides customers the ability to connect LMR Networks and Dispatch Consoles to the ESChat platform in a simplified and secure manner. ORLANDO, Fla., March 25, 2024 /PRNewswire/ — ESChat and JPS Interoperability Solutions have announced availability of a next gener
First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
MELBOURNE, Australia, March 25, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in its named patient program in Italy for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix™[1]). TLX250-CDx is the Company’
ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma with no approved treatment in the U.S.1 OSAKA, Japan, March 25, 2024 /PRNewswire/ — ONO Pharmaceuticals, Co., Ltd. today announced it has completed target patient enrollment of the first arm (Part A) of the PROSP
Euroclear to invest in IZNES, a leading solution enabling an innovative funds distribution model
BRUSSELS, and PARIS, March 25, 2024 /PRNewswire/ — Euroclear and IZNES today announce that Euroclear will acquire a stake in IZNES, a pan-European funds marketplace based on blockchain technology. The transaction will be subject to customary closing conditions and regulatory approvals. Financi
India Ghee Market Expected to Reach INR 6,931 Billion by 2032 with Rising Health Consciousness and Shift Towards Organic Products
DUBLIN, March 25, 2024 /PRNewswire/ — The “Ghee Market in India Report by Type (Cow Ghee, Desi Ghee), Retail and Institutional Sales (Retail, Institutional), and Region 2024-2032″ report has been added to ResearchAndMarkets.com’s offering. The ghee market in India size reac
Elbit Systems Awarded Approximately $300 Million Contract to Supply Defense Solutions for an International Customer
HAIFA, Israel, March 25, 2024 /PRNewswire/ — Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) (“Elbit Systems” or the “Company”) announced today that it has been awarded a contract worth approximately $300 million to supply defense solutions to an international customer.
Citycon has published its 2023 Sustainability Accounts featuring the company’s refined sustainability strategy
CITYCON OYJ Corporate Press Release 25 March 2024 at 9:30 HELSINKI, March 25, 2024 /PRNewswire/ — Citycon Oyj’s 2023 Sustainability Accounts have been published today, reflecting the impact of its updated sustainability strategy. The highlights of the year include the transformation of s
